- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04142398
Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
Investigating Human Papillomavirus (HPV) Infection and HPV-Associated Disease in Indian Men Who Have Sex With Men Who Are HIV-Positive
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the prevalence of HPV-associated premalignant lesions in the anus and penis in Indian HIV-seropositive men who have sex with men (MSM).
SECONDARY OBJECTIVES:
I. Describe risk factors for prevalent premalignant lesions in the anus and penis in Indian HIV-seropositive MSM.
II. Describe the prevalence and incidence of penile and anal HPV infection in Indian HIV-seropositive MSM.
OUTLINE:
Participants receive a questionnaire and undergo a targeted physical and anal clinical exam at months 0, 6, and 12. Participants also undergo a penile skin cell and anal swab at months 0, 6, and 12 for cytology, HPV deoxyribonucleic acid (DNA), and CD4+ T-cell count at months 0 and 6 and HIV viral load testing at months 0 and 12. Participants also undergo high-resolution anoscopy (HRA) and penile clinical exam at month 12.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Mumbai, India, 400 012
- Tata Memorial Hospital
-
Contact:
- Sharmila A. Pimple
- Phone Number: 91-22-24154379
- Email: pimplesa@tmc.gov.in
-
Principal Investigator:
- Sharmila A. Pimple
-
Mumbai, India, 401706
- Udaan Trust
-
Contact:
- Vijay Nair
- Phone Number: 91-22-3209-4538
- Email: airvijaynair@gmail.com
-
Principal Investigator:
- Vijay Nair
-
-
-
-
California
-
San Francisco, California, United States, 94143
- UCSF Medical Center-Parnassus
-
Contact:
- Joel Palefsky
- Phone Number: 877-827-3222
- Email: joel.palefsky@ucsf.edu
-
Principal Investigator:
- Joel Palefsky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV positive, as documented by any licensed HIV test according to the Indian National acquired immune deficiency syndrome (AIDS) Control Organization (NACO) guidelines
- Participants report any sex with a man in the past 6 months
- Participants must speak Hindi, Marathi, or English
- Participants should not have any plans to move out of the area in the next 12 months and commit to attending two additional visits one at 6 months and one at 12 months
Exclusion Criteria:
Active drug or alcohol use or dependence, or other impairment that, in the opinion of the site investigator, would interfere with adherence to study requirements
- Participants with impairments that, in the opinion of the site investigator, are temporary, will be asked to return another day for enrollment
- Inability to provide informed consent
- History of a sex change operation that would preclude collection of penile or scrotal specimens
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Screening (health information collection)
Participants receive a questionnaire and undergo a targeted physical and anal clinical exam at months 0, 6, and 12. Participants also undergo a penile skin cell and anal swab at months 0, 6, and 12 for cytology, HPV DNA, and CD4+ T-cell count at months 0 and 6 and HIV viral load testing at months 0 and 12. Participants also undergo HRA and penile clinical exam at month 12.
|
Correlative studies
Ancillary studies
Undergo penile skin cell and anal swab collection
Other Names:
Undergo HRA with biopsy
Other Names:
Undergo anal and penile clinical exam
Other Names:
Undergo targeted physical exam
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of HPV-associated high-grade anal intraepithelial neoplasia (HGAIN)
Time Frame: Baseline
|
The proportion of men with HPV 6, 11, 16, and/or 18-associated HGAIN will be calculated.
HGAIN is determined by biopsy and HPV typing is based on concurrent DNA analysis of anal swabs.
|
Baseline
|
Prevalence of premalignant lesions of the penis
Time Frame: Baseline
|
Will be calculated using proportions and exact 95% binomial CI.
|
Baseline
|
Prevalence and incidence of human papillomavirus (HPV)
Time Frame: Up to 12 months
|
Will be estimated for specific types, and for all types combined using the life table approach for incidence.
Separate estimates will be made for each anatomical site.
Risk factors for site-specific incident infection will be evaluated using regression models for survival events observed in discrete time (e.g.
pooled logistic regression), incorporating behavioral and biological predictors measured at baseline, and over time at study visits.
Risk factors that will be assessed include behavioral and medical history, CD4+ level, and HIV viral load.
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of men with HGAIN at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18).
Time Frame: Baseline
|
The proportion of men with HGAIN at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18) will be calculated.
HGAIN is determined by biopsy and HPV typing is based on concurrent DNA analysis of anal swabs .
|
Baseline
|
The proportion of men with premalignant lesions of the penis at baseline according to reported number of sex partners in the last 6 months
Time Frame: baseline
|
The proportion of men with premalignant lesions of the penis at baseline according to number of sex partners in the last 6 months will be calculated.
Premalignant lesions of the penis are determined by colposcopic magnification and HPV typing is based on concurrent DNA analysis of penile swabs.
|
baseline
|
The proportion of men with HGAIN at baseline according to reported number of sex partners in the last 6 months
Time Frame: baseline
|
The proportion of men with HGAIN at baseline according to number of sex partners in the last 6 months will be calculated.
HGAIN is determined by biopsy and HPV typing is based on concurrent DNA analysis of anal swabs.
|
baseline
|
The proportion of men with premalignant lesions of the penis at baseline according CD4+ level.
Time Frame: baseline
|
The proportion of men with premalignant lesions of the penis at baseline according to CD4+ level at baseline will be calculated.
Premalignant lesions of the penis are determined by colposcopic magnification and HPV typing is based on concurrent DNA analysis of penile swabs .
|
baseline
|
The proportion of men with HGAIN at baseline according CD4+ level.
Time Frame: baseline
|
The proportion of men with HGAIN at baseline according to CD4+ level at baseline will be calculated.
HGAIN is determined by biopsy and HPV typing is based on concurrent DNA analysis of anal swabs.
|
baseline
|
The proportion of men with premalignant lesions of the penis at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18).
Time Frame: Baseline
|
The proportion of men with premalignant lesions of the penis at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18) will be calculated.
Premalignant lesions of the penis are determined by colposcopic magnification and HPV typing is based on concurrent DNA analysis of penile swabs .
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joel Palefsky, AIDS Malignancy Consortium
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMC-094 (Other Identifier: CTEP)
- UM1CA121947 (U.S. NIH Grant/Contract)
- NCI-2016-01347 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R21CA167653 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States